Abbott, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated Are Dominating The Global Non-Small Cell Lung Cancer Diagnostics Market In 2020

Global Non-Small Cell Lung Cancer Diagnostics Market is expected to grow with a CAGR of 13.2% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-non-small-cell-lung-cancer-diagnostics-market

The global non-small cell lung cancer diagnostics market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.

The major players dealing in the global non-small cell lung cancer diagnostics market are introducing a strong range of products provider along with launching new certificates and adopting strategic initiatives such as acquisition, business expansion, award, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.

For instance:

  • In June 2019, F. Hoffmann-La Roche Ltd launched an in-vitro diagnostic test, ROS1 immunohistochemistry assay, to diagnose VENTANA ROS1 (SP384) Antibody, indicating positive lung cancer. ROS 1 gene mutation is present in non-small cell lung cancer (NSCLC) cases. This new method is efficient as well as cost-effective. This new launch helped the company enhance its product portfolio and offer effective and efficient treatment for non-small cell lung cancer

Abbott Laboratories is the dominating player in the global non-small cell lung cancer diagnostics market. The other key players existing in the market are F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, Dr. Lal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co., Ltd, Oncimmune, Biodesix.

Non-small Cell Lung Cancer Diagnostics Market Abbott Laboratories

Abbott Laboratories, founded in the year 1903, headquarter is in Illinois, U.S. The company is focused on delivering instruments and assay solutions to provide early diagnosis of diseases and for selection of appropriate therapies, and to monitor diseases recurrence. The company has several product categories, including featured products, instrumentation, infectious disease, informatics, oncology, genetics, and genomics in which instrumentation, infectious disease, oncology is the market-focused category.

For instance,

  • In October 2012, Abbott laboratories expanded its business by launching companion diagnostics,  Vysis ALK Break Apart FISH Probe Kit in Europe, to diagnose non-small cell lung cancer patients eligible for XALKORI treatment. This expansion helped the company in expanding their business in Europe and set large consumer base

The company has a wide presence across Asia-Pacific, Europe, America, South Africa, and the Middle East.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd, founded in the year 1896, is headquartered in Basel, Switzerland. The main focus of the company is on developing and integrating diagnostic solutions covering molecular diagnostics, clinical chemistry, immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing, and laboratory automation, and IT and decision support solutions. The company operates its business via several business segments, including pharmaceuticals, diagnostics in which diagnostics are the market-focused segment.

For instance,

  • In June 2019, F. Hoffmann-La Roche Ltd launched an automated digital pathology algorithm, uPath PD-L1 (SP263) image analysis, to diagnose non-small cell lung cancer (NSCLC) and improve the speed and accuracy of diagnosis treatment. This new launch of the algorithm helped the pathologist to assess the disease more effectively.

The company has a presence across Europe, North America, Asia-Pacific, Africa.

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated was founded in the year 1967, headquartered in New Jersey, U.S. The main focus of the company is on providing diagnostics testing, information, and services to patients, healthcare providers, pharmaceutical companies, and life insurance companies. The company has product categories in segments, including solutions for physicians and hospitals, medical conditions, and a focus on speciality, in which medical conditions is the market-focused category.

For instance,

  • In June 2021, Quest Diagnostics Incorporated partnered with Biocept to offer its target selector next-generation sequencing (NGS)-based liquid biopsy targeted lung cancer panel to the customers and also use Biocept’s less invasive, lab-developed assay to conduct genomic profiling in advanced NSCLC patients. This partnership helped the company offer its product to a large consumer base and develop more advanced technology

The company has a presence across Europe, North America, Asia-Pacific.